Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Knee OsteoArthritis Long-term Assessment

NCT: NCT06839222 · WITHDRAWN

NCT IDNCT06839222
StatusWITHDRAWN
Start Date2025-05
Completion2026-11

Brief Summary

The goal of this clinical study is to learn if Hydrogel OA 2% injection is safe and whether it works to improve symptoms of diagnosed knee osteoarthritis in adults when compared to Hyaluronic Acid (Durolane), a treatment that is currently often used for treatment of knee osteoarthritis. The main question it aims to answer is: \- How many study participants will experience side effects related to Hydrogel OA 2% during the study when compared to Hyaluronic Acid (Durolane)? All study participants will receive either one Hydrogel OA 2% or Hyaluronic Acid (Durolane) injection in their knee during the clinical study. Study participants will not know which treatment they have received. Study participants will also receive a call from the researchers and visit the clinic three times to report whether they have experienced any side effects, and complete a questionnaire that will ask questions on whether their symptoms have improved since they received an injection.

Frequently Asked Questions

What is Knee OsteoArthritis Long-term Assessment?

Knee OsteoArthritis Long-term Assessment is a clinical trial registered under NCT06839222. Current status: WITHDRAWN.

What is the status of NCT06839222?

The current status of NCT06839222 (Knee OsteoArthritis Long-term Assessment) is: WITHDRAWN.

When did Knee OsteoArthritis Long-term Assessment start?

Knee OsteoArthritis Long-term Assessment started on 2025-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.